FATE

Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics, Inc. (FATE) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (D+). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.8 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.8
EV / EBITDA -1.2
Rev Growth YoY 9.2%
Gross Margin 0.0%
Price Return 3M -34.9%
Price Return 12M 65.4%
Catalyst Signal 0.00
Market Cap $215.2M
TTM Revenue $6.5M
Price / Sales 33.2
ROE -60.8%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.8) C (2.3) D+ (1.7) C+ (2.6) C+ (2.6) C (2.4)
2026-11-04 C+ (2.8) C- (1.9) D+ (1.6) B- (2.9) C+ (2.7) C (2.4)
2026-10-28 C+ (2.8) D+ (1.8) D+ (1.7) B (3.5) C+ (2.7) C (2.5)
2026-10-21 C+ (2.8) D+ (1.8) D+ (1.7) B (3.4) C+ (2.6) C (2.5)
2026-10-14 C+ (2.8) D+ (1.8) D+ (1.7) B- (3.0) C+ (2.6) C (2.4)
Page 1 of 8
…